The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

KRAS G12C is the most common form of KRAS mutation ... hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market. Join the conversation, on Tuesday 28th January @ 10 am ...

FDA approves a new treatment for KRAS G12C-mutated metastatic colorectal cancer, showing significant progression-free ...